Answer
Trodelvy (sacituzumab govitecan) is infused intravenously over 3 hours initially and over 1–2 hours subsequently if prior infusions were tolerated, with observation during and for at least 30 minutes after each infusion for infusion-related reactions.
Sources for this answer
- Trodelvy 180 mg powder for concentrate for solution for infusionGilead Sciences Ltd · emc · SmPC §4.2 Posology and method of administration · Version 11Document updated
Sources checked